lifestyle.newsblaze.com

Author: NOVO NORDISK INC.

Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg

November 27, 2025
Novo Nordisk’s CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

November 14, 2025
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

November 8, 2025
Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting

October 29, 2025